Daiichi Life Insurance Co. Ltd. Trims Position in Pfizer Inc. $PFE

Daiichi Life Insurance Co. Ltd. lessened its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 29.9% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 170,206 shares of the biopharmaceutical company's stock after selling 72,630 shares during the period. Daiichi Life Insurance Co. Ltd.'s holdings in Pfizer were worth $4,099,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Evolution Wealth Management Inc. raised its stake in Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 566 shares during the period. Godfrey Financial Associates Inc. bought a new position in Pfizer in the 4th quarter worth approximately $26,000. Keb Asset Management LLC bought a new position in Pfizer in the 2nd quarter worth approximately $26,000. HFM Investment Advisors LLC grew its holdings in Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 427 shares in the last quarter. Finally, Global Trust Asset Management LLC grew its holdings in Pfizer by 126.7% during the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 650 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Down 0.4%

PFE stock opened at $27.97 on Tuesday. Pfizer Inc. has a twelve month low of $23.58 and a twelve month high of $28.75. The stock has a market capitalization of $159.41 billion, a price-to-earnings ratio of 36.80 and a beta of 0.34. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The firm's fifty day simple moving average is $25.34 and its two-hundred day simple moving average is $26.26.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business's revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the business earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.1%. The ex-dividend date is Friday, July 24th. Pfizer's dividend payout ratio is presently 226.32%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. HSBC downgraded shares of Pfizer from a "buy" rating to a "hold" rating and dropped their price objective for the company from $32.00 to $28.00 in a report on Monday, July 6th. BMO Capital Markets reduced their target price on Pfizer from $34.00 to $30.00 and set an "outperform" rating on the stock in a report on Monday, July 13th. Weiss Ratings downgraded Pfizer from a "hold (c)" rating to a "hold (c-)" rating in a research report on Monday, August 17th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $27.00 price objective on shares of Pfizer in a report on Monday, July 6th. Finally, Guggenheim lowered their target price on Pfizer from $35.00 to $31.00 and set a "buy" rating for the company in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $28.28.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source